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The development of therapeutic agents against SARS-CoV-2/COVID-19 faces numerous barriers and a multidis-
ciplinary approach to evaluating drug efficacy and toxicity is essential. Experimental and preclinical data should
be integrated into a comprehensive analysis, where drug potency, the timing of therapy initiation, drug combina-
tions, variability in systemic and local drug exposure and short- and long-term toxicities represent fundamental
factors for the rational identification of candidates and prioritization of clinical investigations. Although the iden-
tification of SARS-CoV-2 therapeutics is a priority, rigorous and transparent methodologies are crucial to ensure
that accelerated research programmes result in high-quality and reproducible findings.
The SARS-CoV-2/COVID-19 pandemic is one of the biggest chal-
lenges in recent history and multiple tools to control the spread
and impact of the virus are currently under investigation. Although
therapeutic agents have the potential to be useful tools in amelio-
rating symptoms and reducing mortality in patients, the develop-
ment of effective drugs against SARS-CoV-2 has multiple
challenges that require careful analysis. Here we summarize some
of the key pharmacological challenges related to SARS-CoV-2
therapeutics.
Successful therapies for most other viral infections have been
based on the combination of multiple agents.1 Only in a very lim-
ited number of viral infections has monotherapy been shown to ef-
fectively inhibit viral replication and a combination of therapy
targeting different steps of the viral life cycle is often critical to
achieve clinically relevant viral suppression.2 Is this important in re-
lation to SARS-CoV-2? Is there the likelihood of selecting resistance
mutations? We currently have a limited understanding of muta-
tion frequency and the possible downstream effects on antiviral
resistance and infectivity.3 The selection of viral mutations may
depend on the difference between the achieved plasma exposure
and the potency of the drug. We clearly need to be cautious when
conducting clinical trials of monotherapy with drugs of limited po-
tency and often unfavourable pharmacokinetic/pharmacody-
namic (PK/PD) profile.
The timing of initiation of therapy represents a pivotal element
in defining the therapeutic effects. How long from the beginning of
infection will an antiviral approach be valid? The interval between
the acquisition of the SARS-CoV-2 infection and treatment initi-
ation will vary but, currently, the great majority of patients will be
identified and receive treatment after the onset of symptoms and
often when seriously ill.4,5 Therefore it is likely that the viral load
will already be elevated in numerous anatomical sites and down-
stream physiopathological processes already triggered. Earlier
treatment may allow for a drug with partial activity to change the
trajectory of the clinical disease even if the virus is not completely
suppressed. However, pharmacological strategies based only on
the inhibition of viral replication will likely have a limited overall ef-
fect on the clinical outcome and a broader consideration of poten-
tial therapeutic strategies is essential. The pharmacological
management of the downstream cytokine storm, inflammation,
coagulation and physiopathological effects on other anatomical
sites should be carefully considered in parallel or even with higher
priority compared with the inhibition of viral replication.6,7
Antiviral drug potency is routinely measured through in vitro
assays, which have methodological limitations that should be
carefully considered. These assays utilize cell media containing
limited amounts of proteins compared with the physiological en-
vironment of plasma and tissues in the human body and this can
result in a much higher fraction of unbound drug compared with
that in plasma and tissue. Consequently, the correction of EC50
and EC90 for protein binding (protein-adjusted EC90, PAEC90) is an
important step to help in interpreting experimental data. This will
be particularly relevant for drugs characterized by high protein
binding (such as many of the suggested agents for repurposing)
and a careful evaluation of available data is necessary, as done
routinely in many other disease areas (e.g. HIV).8 Additionally, the
in vitro potency assays are based on immortalized cell lines, which
are often not derived from human cells and as such do not repre-
sent the main target for the SARS-CoV-2 replication (e.g. Vero cell
lines are derived from the kidneys of the African Green Monkey).9
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The extrapolation of EC50/EC90 values measured in such an envir-
onment to the in vivo situation should be taken cautiously unless
there is a detailed understanding and characterization of the cor-
relation between in vitro and in vivo antiviral potencies. Lessons
learned from other disease areas can provide a rational framework
to better understand the PK/PD requirements for guiding the iden-
tification of potential treatment options and only drugs that result
in plasma and tissue concentrations several-fold above the PAEC90
for the entire dose interval are likely to represent suitable candi-
dates. It is important that adequate drug concentrations are pre-
sent in all sites of viral replication. An integration of experimental
in vitro approaches with animal models of SARS-CoV-2 should be
pursued to further refine our understanding of PK/PD relationships
and consequently limit the probability of overstretching the rele-
vance of in vitro data, especially for drugs with low potency (EC90 in
the lM range). In the great majority of cases, antivirals that have
found successful application in other diseases are characterized by
potency in the low nM range, further suggesting caution is needed
when considering clinical investigation of drugs with in vitroactivity
in the lM range.10–14 In vitro, animal and clinical data can be inte-
grated into quantitative pharmacology approaches, but it is essen-
tial that the modelling framework is based on solid foundations
and assumptions in order to provide a reliable representation of
PK/PD of novel agents and therefore support sustainable strategies
and prioritize clinical trials.
Many patients who could potentially benefit from receiving
treatments against SARS-CoV-2 will have complex physiological
characteristics and, in many cases, concomitant comorbidities and
comedications.15–17 Additionally, an increasing number of studies
are describing how the SARS-CoV-2 infection can cause damage to
different organs and tissues including the CNS, kidneys and
heart.18–20 Therefore, a comprehensive evaluation of the safety
profile of potential therapeutic agents is of paramount import-
ance, especially when considering repurposed drugs at higher
doses than for the treatment of their original indication(s) and
which can be characterized by concentration-dependent toxicities
(e.g. QT prolongation).21 However, we also draw attention to the
fact that known toxicities of drugs used long term, often in non-
infectious disease indications, may be less relevant if used short
term against viral infections. The correct management of drug–
drug interactions is also an important consideration when intro-
ducing these pharmacological agents in complex patients with
multiple comorbidities. To date, hundreds of clinical trials are on-
going for the investigation of repurposed and novel therapeutic
agents against SARS-CoV-2 and appropriately designed random-
ized clinical studies represent the most appropriate strategies to
fully clarify the value of selected candidates. International efforts
should be focused on the optimization of clinical investigations,
enhancing the quality of study design, increasing the number of
patients included in studies and reducing the number of studies for
each drug and/or combination to avoid unnecessary duplication. It
is also important to note that drugs that have insufficient activity
for treatment may still have benefit in prevention/prophylaxis.
All the above elements indicate the importance of multidiscip-
linary collaborative initiatives to provide a broad and effective vi-
sion to identify and meet the challenges related to developing and
refining pharmacological tools against SARS-CoV-2. The input from
molecular, clinical and quantitative pharmacology, immunology,
toxicology, medicinal chemistry and infectious disease is vitally
important to give the best outcome. In addition, although fully
aware of the urgency to develop tools to mitigate the damage
caused by SARS-CoV-2, we also recognize the potential of compro-
mising quality in the pursuit of accelerating research programmes.
Publication and dissemination of data based on a less-than-
rigorous approach is detrimental, not only for the constructive and
progressive advance of pharmacological/medical knowledge but
also for the messaging to the general public as well as other com-
munities of specialists. In this regard, peer review is essential to en-
sure that scientific findings are robust and of high quality so that
we do not compromise the vital trust that the public has in medical
and scientific experts.22
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